152459-95-5 Imatinib AKSci J90067
 
 
Loading Please Wait...
  J90067    
Imatinib
, 95%, for synthesis
 
STI571
Glivec




IDENTITY
CAS Number:152459-95-5
MDL Number:MFCD05662257
MF:C29H31N7O
MW:493.6
SPECIFICATIONS & PROPERTIES
Purity:95%, for synthesis
Physical Form:White to off-white to light yellow powder
Melting Point:208-213°C
Long-Term Storage:Store at room temperature

BIOLOGICAL INFO
Solubility:DMSO: 3mg/mL; H2O: <1mg/mL; EtOH: <1mg/mL
Application(s):Protein Kinase Inhibitor; Tyrosine kinase enzymes specific inhibitor
Form:Free Base

REVIEW

 Imatinib works by blocking a central tyrosine kinase enzyme, in this case, BCR-ABL from phosphorylating subsequent proteins and initiating the signaling cascade necessary for cancer development. Because the BCR-ABL tyrosine kinase enzyme exists only in cancer cells and not in healthy cells, Imatinib is able to function as a targeted cancer therapy-only cancer cells are killed through the drug''s action. In this regard, Imatinib was one of the first cancer therapies to show the potential for such targeted action and of is often cited as a paradigm for research in cancer therapeutics.

REFERENCES
[1]Novartis Pharma AG. Gleevec® (imatinib mesylate) tablets prescribing information. East Hanover, NJ; 2006 Sep. Anon. Drugs of choice for cancer. Treat Guidel Med Lett. 2003; 1:41-52
[2] Goldman, J.M. & Melo, J.V. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med 349, 1451-1464 (2003)
[3] Fausel, C. Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm 64, S9-15 (2007)
[4] Stegmeier, F., et al. (2010). Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib. Clin Pharmacol Ther 87(5): 543-552.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H302

Precautionary Statements
P264; P270; P301+P312; P330; P501


Current as of June 24, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Protein Kinase Inhibitors


PubChem